Cargando…
Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy
Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving non-malignant cells unharmed. With the first U.S. Food and Drug Administration-approved OV, dozens of clinical trials ongoing, and an abundance of translational research in the field, OV therapy is pois...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415316/ https://www.ncbi.nlm.nih.gov/pubmed/28480326 http://dx.doi.org/10.1016/j.omto.2017.03.002 |